7041-BA3-CLR Lighting Golden Monroe with Light Vanity Bathroom Wide 23" Light 3 Wall Fixtures


  1. Home
  2. 7041-BA3-CLR Lighting Golden Monroe with Light Vanity Bathroom Wide 23" Light 3
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Golden Lighting 7041-BA3-CLR Monroe 3 Light 23" Wide Bathroom Vanity Light with
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Type: Indoor Lighting
Bulb Base: Medium (E26) Brand:

Golden Lighting

Height: 8.625 MPN:

7041-BA3 BLK-CLR

Number of Bulbs: 3 Color:

Black

Wattage: 180 Material: Steel
Voltage: 120 Model:

7041-BA3-CLR

Collection: Monroe Width: 23
Manufacturer Finish: Black UPC:

844375057128






published on tue nov 09 2021

7041-BA3-CLR Lighting Golden Monroe with Light Vanity Bathroom Wide 23" Light 3 Wall Fixtures

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

7041-BA3-CLR Lighting Golden Monroe with Light Vanity Bathroom Wide 23" Light 3 Wall Fixtures

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS